Tactile Systems Technology (NASDAQ:TCMD) Shares Climb 12.9% – Should You Buy?

Tactile Systems Technology, Inc. (NASDAQ:TCMD – Get Free Report)’s share price was up 12.9% on Wednesday. The stock traded as high as $27.25 and last traded at $27.9810. Approximately 68,452 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 300,885 shares. The stock had previously closed at $24.78.

Tactile Systems Technology News Roundup

Here are the key news stories impacting Tactile Systems Technology this week:

  • Positive Sentiment: TCMD moved above its 20-day moving average after finding support, a technical signal that may indicate improving short-term momentum. Article: TCMD overtakes 20-day moving average
  • Positive Sentiment: Analyst earnings-estimate revisions are trending positively, and average price targets suggest substantial upside, though price targets are not reliable predictors on their own. Article: Analyst targets and estimate revisions
  • Positive Sentiment: Third-quarter adjusted earnings were $0.31 per share, above the $0.28 consensus. Lymphedema revenue rose 13% year over year to $81.8 million, and technology improvements cut medical-record review times by about 50%. Article: Three investor takeaways
  • Neutral Sentiment: Full-year 2026 revenue guidance of $360 million–$366 million is broadly in line with the $362.5 million consensus. BTIG lowered its price target to $31 from $35 but retained a Buy rating. Article: BTIG rating and price target
  • Negative Sentiment: Quarterly revenue of $91.86 million narrowly missed estimates, while earnings per share declined from $0.36 a year earlier. Higher sales and administrative expenses weighed on operating income; the airway-clearance business also shrank, with AffloVest inventory a further concern. Article: Spending outpaces sales

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TCMD. Weiss Ratings cut Tactile Systems Technology from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday. BTIG Research decreased their target price on Tactile Systems Technology from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Wall Street Zen upgraded Tactile Systems Technology from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Tactile Systems Technology currently has an average rating of “Moderate Buy” and a consensus price target of $36.80.

Get Our Latest Stock Analysis on TCMD

Tactile Systems Technology Stock Up 13.1%

The company’s fifty day moving average price is $22.75 and its 200 day moving average price is $25.88. The company has a market capitalization of $634.52 million, a P/E ratio of 27.45 and a beta of 0.95.

Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. The business had revenue of $91.86 million during the quarter, compared to analysts’ expectations of $91.99 million. Tactile Systems Technology had a return on equity of 10.82% and a net margin of 6.68%. Research analysts predict that Tactile Systems Technology, Inc. will post 1.10 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sheri Dodd sold 10,978 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $29.44, for a total transaction of $323,192.32. Following the completion of the sale, the chief executive officer directly owned 232,907 shares in the company, valued at approximately $6,856,782.08. This represents a 4.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TCMD. Allspring Global Investments Holdings LLC lifted its position in Tactile Systems Technology by 4.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 19,071 shares of the company’s stock worth $425,000 after purchasing an additional 749 shares during the period. State of Wyoming grew its stake in Tactile Systems Technology by 68.1% during the third quarter. State of Wyoming now owns 18,941 shares of the company’s stock worth $422,000 after buying an additional 7,670 shares in the last quarter. Inspire Investing LLC bought a new position in Tactile Systems Technology in the 3rd quarter valued at about $2,456,000. Pinnacle Associates Ltd. increased its holdings in Tactile Systems Technology by 0.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 327,967 shares of the company’s stock valued at $7,310,000 after buying an additional 850 shares during the period. Finally, State of Alaska Department of Revenue increased its holdings in Tactile Systems Technology by 18.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 7,113 shares of the company’s stock valued at $158,000 after buying an additional 1,132 shares during the period. Institutional investors and hedge funds own 83.43% of the company’s stock.

Tactile Systems Technology Company Profile

(Get Free Report)

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.

See Also

Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.